Science
Ahmet Dirican: Could OptiTROP-Lung06 Change First-Line Treatment in PD-L1-Negative NSCLC
Ahmet Dirican/X and Caicun Zhou/iaslc.org

Ahmet Dirican: Could OptiTROP-Lung06 Change First-Line Treatment in PD-L1-Negative NSCLC

Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:

“At ESMO26, Prof. Caicun Zhou presented striking Phase III results: Sac-TMT + pembrolizumab vs chemo + pembrolizumab: PFS: 15.0 vs 5.7 months (HR 0.49) A potential practice-changing result.”

Ahmet Dirican

This also can be interesting:

OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab Outperforms Chemoimmunotherapy in PD-L1–Negative NSCLC

Ahmet Dirican: Could OptiTROP-Lung06 Change First-Line Treatment in PD-L1-Negative NSCLC

Ahmet Dirican Caicun Zhou cancer ESMO26 Lung cancer NSCLC OncoDaily Oncology OptiTROP-Lung06 pembrolizumab